A discussion regarding the comparative effectiveness of different CFTR modulator combinations, specifically Elexacaftor + Tezacaftor + Ivacaftor (ETI) versus Ivacaftor + Lumacaftor or Ivacaftor + Tezacaftor, in restoring CFTR function for patients with the N1303K variant.